{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:44:17Z","timestamp":1793634257314,"version":"4.5.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.metabol.2022.155248","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T02:33:06Z","timestamp":1656988386000},"page":"155248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)\/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?"],"prefix":"10.1016","volume":"136","author":[{"given":"Laura","family":"Valenzuela-Vallejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guatibonza-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2022.155248_bb0005","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2022.155248_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155248_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154822","article-title":"Preparing for the NASH epidemic: a call to action","volume":"122","author":"Kanwal","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155248_bb0020","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155248_bb0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000443344","article-title":"Clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"9","author":"EASL-EASD-EASO","year":"2016","journal-title":"Obes Facts"},{"key":"10.1016\/j.metabol.2022.155248_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/nu9040387","article-title":"Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments","volume":"9","author":"Kitade","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2022.155248_bb0035","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2022.155248_bb0040","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ihj.2014.08.006","article-title":"Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-\u03b1","volume":"66","author":"Ajmal","year":"2014","journal-title":"Indian Heart J"},{"key":"10.1016\/j.metabol.2022.155248_bb0045","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2022.155248_bb0050","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155248_bb0055","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.metabol.2022.155248_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154781","article-title":"Addressing the epidemic of fatty liver disease: a call to action, a call to collaboration, a call to moving the field forward","volume":"122","author":"Boutari","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155248_bb0065","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dci21-0020","article-title":"Preparing for the NASH epidemic: a call to action","volume":"44","author":"Kanwal","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155248_bb0070","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2022.155248_bb0075","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves Beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155248_bb0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155248_bb0085","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155248_bb0090","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155248_bb0095","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2022.155248_bb0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2022.155248_bb0105","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/dom.14174","article-title":"The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes","volume":"22","author":"Wilson","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155248_bb0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.metabol.2022.155248_bb0115","series-title":"A study of tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity (SUMMIT)","year":"2021"},{"key":"10.1016\/j.metabol.2022.155248_bb0120","series-title":"A quick guide to the SURPASS and SURMOUNT trialsPhase 3 trials of tirzepatide in type 2 diabetes and obesity","author":"McDermid","year":"2020"},{"key":"10.1016\/j.metabol.2022.155248_bb0125","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155248_bb0130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155248_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like Peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.metabol.2022.155248_bb0140","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155248_bb0145","series-title":"A study of tirzepatide (LY3298176) in participants with nonalcoholic steatohepatitis (NASH) (SYNERGY-NASH)","year":"2019"},{"key":"10.1016\/j.metabol.2022.155248_bb0150","series-title":"FDA approves novel, dual-targeted treatment for type 2 diabetes","year":"2022"},{"key":"10.1016\/j.metabol.2022.155248_bb0155","series-title":"Tirzepatide's retail price set at about $12,666 per year","author":"Zoler","year":"2022"},{"key":"10.1016\/j.metabol.2022.155248_bb0160","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155248_bb0165","series-title":"A study of tirzepatide (LY3298176) versus insulin lispro (U100) in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin (SURPASS-6)","year":"2020"},{"key":"10.1016\/j.metabol.2022.155248_bb0170","series-title":"A study of tirzepatide (LY3298176) compared to dulaglutide in participants with type 2 diabetes (SURPASS J-mono)","year":"2019"},{"key":"10.1016\/j.metabol.2022.155248_bb0175","series-title":"A phase 3, long-term safety study of tirzepatide in combination with monotherapy of oral antihyperglycemic medications in patients with type 2 diabetes mellitus (SURPASS J-combo)","year":"2019"},{"key":"10.1016\/j.metabol.2022.155248_bb0180","series-title":"A study of tirzepatide (LY3298176) in participants with type 2 diabetes on metformin with or without sulfonylurea (SURPASS-AP-Combo)","year":"2019"},{"key":"10.1016\/j.metabol.2022.155248_bb0185","series-title":"A study of tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with type 2 diabetes (SURPASS-CVOT)","year":"2020"},{"key":"10.1016\/j.metabol.2022.155248_bb0190","series-title":"A study of tirzepatide (LY3298176) in Chinese participants without type 2 diabetes who have obesity or overweight (SURMOUNT-CN) (SURMOUNT-CN)","year":"2021"},{"key":"10.1016\/j.metabol.2022.155248_bb0195","series-title":"A study of tirzepatide (LY3298176) in participants with type 2 diabetes who have obesity or are overweight (SURMOUNT-2)","year":"2021"},{"key":"10.1016\/j.metabol.2022.155248_bb0200","series-title":"A study of tirzepatide (LY3298176) in participants after a lifestyle weight loss program (SURMOUNT-3)","year":"2021"},{"key":"10.1016\/j.metabol.2022.155248_bb0205","series-title":"A study of tirzepatide (LY3298176) in participants with obesity or overweight for the maintenance of weight loss (SURMOUNT-4)","year":"2021"},{"issue":"8","key":"10.1016\/j.metabol.2022.155248_bb9005","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.metabol.2016.01.010","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma","volume":"65","author":"Zoller","year":"2016","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.metabol.2022.155248_bb9010","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.metabol.2015.09.017","article-title":"Non-alcoholic fatty liver disease and risk of cardiovascular disease","volume":"65","author":"Lonardo","year":"2016","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.metabol.2022.155248_bb9015","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.metabol.2015.10.032","article-title":"Exercise and diet in the management of nonalcoholic fatty liver disease","volume":"65","author":"Mahady","year":"2016","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.metabol.2022.155248_bb9020","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.metabol.2016.04.004","article-title":"Pharmacological management of nonalcoholic fatty liver disease","volume":"65","author":"Barb","year":"2016","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.metabol.2022.155248_bb9025","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.metabol.2015.09.004","article-title":"The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome","volume":"65","author":"Aguilar-Olivos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155248_bb9030","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154843","article-title":"Incretin-based therapies in 2021 - Current status and perspectives for the future","volume":"122","author":"Rizzo","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155248_bb9035","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155248","article-title":"Recent guidelines for non-alcoholic fatty liver disease (NAFLD): are they already outdated and in need of supplementation?","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522001263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522001263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:31:28Z","timestamp":1758429088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049522001263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":48,"alternative-id":["S0026049522001263"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155248","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)\/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155248"}}